Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
Author(s) -
Gammal RS,
Court MH,
Haidar CE,
Iwuchukwu OF,
Gaur AH,
Alvarellos M,
Guillemette C,
Lennox JL,
WhirlCarrillo M,
Brummel SS,
Ratain MJ,
Klein TE,
Schackman BR,
Caudle KE,
Haas DW
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.269
Subject(s) - guideline , atazanavir , medicine , pharmacogenetics , medical physics , family medicine , biology , genotype , biochemistry , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , pathology , gene
The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin‐related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles ( UGT1A1*28 or *37 ). We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org ).